Soleno Therapeutics (SLNO) Cash from Financing Activities (2014 - 2026)

Soleno Therapeutics (SLNO) has reported Cash from Financing Activities for 12 consecutive years, with -$1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 132.41% year-over-year to -$1.0 million; the TTM figure through Mar 2026 stood at $132.9 million (down 38.27% YoY), while the FY2025 annual figure was $137.2 million, down 35.61% from the prior year.
• Cash from Financing Activities advanced to -$1.0 million in Q1 2026 per SLNO's latest filing, from -$99.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $218.2 million in Q3 2025 and bottomed at -$99.9 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $36.2 million across 5 years, with a median of $14.0 million in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 14200.0% — and 2023, when it soared 11420.76%.
• Soleno Therapeutics' Cash from Financing Activities stood at $342000.0 in 2022, then jumped by 36028.07% to $123.6 million in 2023, then tumbled by 53.82% to $57.1 million in 2024, then sank by 275.07% to -$99.9 million in 2025, then surged by 98.96% to -$1.0 million in 2026.
• Business Quant data shows SLNO's Cash from Financing Activities at -$1.0 million in Q1 2026, -$99.9 million in Q4 2025, and $218.2 million in Q3 2025.